Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-23

Clinical Trial Update: Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies [Phase 3]

View source ↗

Summary

A Phase III study of etrolizumab in ulcerative colitis has been terminated; results were posted after termination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Etrolizumab (etrolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Ulcerative Colitis | Phase 3 | Status: TERMINATED | Results posted: 2024-10-23